Abstract:
Deferasirox is an iron chelating agent used for the treatment of chronic iron overload in patients. The objective of present study is to design Deferasirox dispersible tablets to deliver optimum concentration of drug at the desired site, comparable to the innovator product. Various formulations of drug with excipients were evaluated for compatibility and formulations prepared using either the direct compression or wet granulation method and evaluated for pre and post compression parameters and the dissolution data, subjected to kinetic evaluation and compared with that of the innovator product. The drug and the excipients were found to be compatible. Formulation 8prepared by using wet granulation method exhibited disintegration time of (35 sec), dispersion time (67 sec) and percentage of drug release (98.3 %) was found to be satisfactory. So, the batch size was increased in order to check for the reproducibility of the formulation. Optimized formulation followed 1^st order kinetics.

Keywords: Deferasirox, Chelating Agent, Dispersible Tablets, Dissolution, Stability, Innovator.